Équipe
Ludovic MARTINET & Hervé avet-LOISEAU

GENIM :

Oncogénomique Et Immunologie Du Myélome

Le laboratoire d’Excellence Toulouse Cancer est un projet qui vise à comprendre les mécanismes de résistance et de rechute dans les cancers.

Les spécificités

de notre axe de recherche

Myélome multiple

Modifications génomiques

Sélection clonale

Résistance

Immunité

Lymphocyte cytotoxique

Echappement immunitaire

Immunothérapie

DES PROJETS
DE RECHERCHE

PRODUCTIONS SCIENTIFIQUES

PUBLICATIONS 2021
Mohty, Mohamad, Hervé Avet-Loiseau, and Jean-Luc Harousseau. “Requirements for Operational Cure in Multiple Myeloma.” Blood 138, no. 16 (October 21, 2021): 1406–11. https://doi.org/10.1182/blood.2021012854.
Botta, Cirino, Catarina Da Silva Maia, Juan-José Garcés, Rosalinda Termini, Cristina Perez, Irene Manrique, Leire Burgos, et al. “FlowCT for the Analysis of Large Immunophenotypic Datasets and Biomarker Discovery in Cancer Immunology.” Blood Advances, September 29, 2021, bloodadvances.2021005198. https://doi.org/10.1182/bloodadvances.2021005198.
Caulier, Alexis, Murielle Roussel, Pierre Morel, Naelle Lombion, Benoit Branco, Jean Galtier, Cyrille Hulin, et al. “EPIDEMIOLOGICAL LANDSCAPE OF YOUNG MULTIPLE MYELOMA PATIENTS DIAGNOSED EARLIER THAN 40 YEARS: THE FRENCH EXPERIENCE.” Blood, September 3, 2021, blood.2021011285. https://doi.org/10.1182/blood.2021011285.
Derrien, Jennifer, Catherine Guérin-Charbonnel, Victor Gaborit, Loïc Campion, Magali Devic, Elise Douillard, Nathalie Roi, et al. “The DNA Methylation Landscape of Multiple Myeloma Shows Extensive Inter- and Intrapatient Heterogeneity That Fuels Transcriptomic Variability.” Genome Medicine 13, no. 1 (August 9, 2021): 127. https://doi.org/10.1186/s13073-021-00938-3.
Chalopin, Thomas, Nicolas Vallet, Olivier Theisen, Marlène Ochmann, Mourad Tiab, Pascal Godmer, Carole Barin, et al. “No Survival Improvement in Patients with High-Risk Multiple Myeloma Harbouring Del(17p) and/or t(4;14) over the Two Past Decades.” British Journal of Haematology 194, no. 3 (August 2021): 635–38. https://doi.org/10.1111/bjh.17488.
Anderson, Kenneth C., Daniel Auclair, Stacey J. Adam, Amit Agarwal, Melissa Anderson, Herve Avet-Loiseau, Mark Bustoros, et al. “Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration.” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, July 28, 2021, clincanres.1059.2021. https://doi.org/10.1158/1078-0432.CCR-21-1059.
Cavo, Michele, Jesus F. F. San-Miguel, Saad Z. Usmani, Katja C. Weisel, Meletios A. A. Dimopoulos, Hervé Avet-Loiseau, Bruno Paiva, et al. “Prognostic Value of Minimal Residual Disease Negativity in Myeloma: Combined Analysis of POLLUX, CASTOR, ALCYONE, MAIA.” Blood, July 21, 2021, blood.2021011101. https://doi.org/10.1182/blood.2021011101.
San-Miguel, Jesus F., Hervé Avet-Loiseau, Bruno Paiva, Shaji K. Kumar, Meletios A. A. Dimopoulos, Thierry Facon, Maria-Victoria Mateos, et al. “Sustained Minimal Residual Disease Negativity With Daratumumab in Newly Diagnosed Multiple Myeloma: MAIA and ALCYONE.” Blood, July 16, 2021, blood.2020010439. https://doi.org/10.1182/blood.2020010439.
Corre, Jill, Aurore Perrot, Cyrille Hulin, Denis Caillot, Anne-Marie Stoppa, Thierry Facon, Xavier Leleu, et al. “Improved Survival in Multiple Myeloma during the 2005-2009 and 2010-2014 Periods.” Leukemia, June 7, 2021. https://doi.org/10.1038/s41375-021-01250-0.
Melaiu, Ombretta, Angelica Macauda, Juan Sainz, Diego Calvetti, Maria Sole Facioni, Giuseppe Maccari, Rob Ter Horst, et al. “Common Gene Variants within 3’-Untranslated Regions as Modulators of Multiple Myeloma Risk and Survival.” International Journal of Cancer 148, no. 8 (April 15, 2021): 1887–94. https://doi.org/10.1002/ijc.33377.
Giaccherini, Matteo, Angelica Macauda, Enrico Orciuolo, Marcin Rymko, Karolina Gruenpeter, Charles Dumontet, Malgorzata Raźny, et al. “Genetically Determined Telomere Length and Multiple Myeloma Risk and Outcome.” Blood Cancer Journal 11, no. 4 (April 14, 2021): 74. https://doi.org/10.1038/s41408-021-00462-y.
Avet-Loiseau, Hervé, Jesus San-Miguel, Tineke Casneuf, Shinsuke Iida, Sagar Lonial, Saad Z. Usmani, Andrew Spencer, et al. “Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR.” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 39, no. 10 (April 1, 2021): 1139–49. https://doi.org/10.1200/JCO.20.01814.
Schavgoulidze, Anaïs, Titouan Cazaubiel, Aurore Perrot, Hervé Avet-Loiseau, and Jill Corre. “Multiple Myeloma: Heterogeneous in Every Way.” Cancers 13, no. 6 (March 13, 2021). https://doi.org/10.3390/cancers13061285.
Corre, Jill, Aurore Perrot, Denis Caillot, Karim Belhadj, Cyrille Hulin, Xavier Leleu, Mohamad Mohty, et al. “Del(17p) without TP53 Mutation Confers a Poor Prognosis in Intensively Treated Newly Diagnosed Patients with Multiple Myeloma.” Blood 137, no. 9 (March 4, 2021): 1192–95. https://doi.org/10.1182/blood.2020008346.
Casneuf, Tineke, Homer C. Adams, Niels W. C. J. van de Donk, Yann Abraham, Jaime Bald, Greet Vanhoof, Koen Van der Borght, et al. “Deep Immune Profiling of Patients Treated with Lenalidomide and Dexamethasone with or without Daratumumab.” Leukemia 35, no. 2 (February 2021): 573–84. https://doi.org/10.1038/s41375-020-0855-4.
Corre, Jill, Nikhil C. Munshi, and Herve Avet-Loiseau. “Risk Factors in Multiple Myeloma: Is It Time for a Revision?” Blood 137, no. 1 (January 7, 2021): 16–19. https://doi.org/10.1182/blood.2019004309.
Klionsky, Daniel J., Amal Kamal Abdel-Aziz, Sara Abdelfatah, Mahmoud Abdellatif, Asghar Abdoli, Steffen Abel, Hagai Abeliovich, et al. “Guidelines for the Use and Interpretation of Assays for Monitoring Autophagy (4th Edition)1.” Autophagy 17, no. 1 (January 2021): 1–382. https://doi.org/10.1080/15548627.2020.1797280.
Ludwig, Heinz, Mario Boccadoro, Philippe Moreau, Jesus San-Miguel, Michele Cavo, Charlotte Pawlyn, Sonja Zweegman, et al. “Recommendations for Vaccination in Multiple Myeloma: A Consensus of the European Myeloma Network.” Leukemia 35, no. 1 (January 2021): 31–44. https://doi.org/10.1038/s41375-020-01016-0.
PUBLICATIONS 2020
Chari, Ajai, Mehmet Kemal Samur, Joaquin Martinez-Lopez, Gordon Cook, Noa Biran, Kwee Yong, Vania Hungria, et al. “Clinical Features Associated with COVID-19 Outcome in Multiple Myeloma: First Results from the International Myeloma Society Data Set.” Blood 136, no. 26 (December 24, 2020): 3033–40. https://doi.org/10.1182/blood.2020008150.
Munshi, Nikhil C., Herve Avet-Loiseau, Kenneth C. Anderson, Paola Neri, Bruno Paiva, Mehmet Samur, Meletios Dimopoulos, et al. “A Large Meta-Analysis Establishes the Role of MRD Negativity in Long-Term Survival Outcomes in Patients with Multiple Myeloma.” Blood Advances 4, no. 23 (December 8, 2020): 5988–99. https://doi.org/10.1182/bloodadvances.2020002827.
Cazaubiel, Titouan, Olga Mulas, Lydia Montes, Anaïs Schavgoulidze, Hervé Avet-Loiseau, Jill Corre, and Aurore Perrot. “Risk and Response-Adapted Treatment in Multiple Myeloma.” Cancers 12, no. 12 (November 24, 2020). https://doi.org/10.3390/cancers12123497.
Kaufman, Jonathan L., Meletios A. Dimopoulos, Darrell White, Lotfi Benboubker, Gordon Cook, Merav Leiba, James Morton, et al. “Daratumumab, Lenalidomide, and Dexamethasone in Relapsed/Refractory Myeloma: A Cytogenetic Subgroup Analysis of POLLUX.” Blood Cancer Journal 10, no. 11 (November 3, 2020): 111. https://doi.org/10.1038/s41408-020-00375-2.
Weulersse, Marianne, Assia Asrir, Andrea C. Pichler, Lea Lemaitre, Matthias Braun, Nadege Carrie, Marie-Veronique Joubert, et al. “Eomes-Dependent Loss of the Co-Activating Receptor CD226 Restrains CD8(+) T Cell Anti-Tumor Functions and Limits the Efficacy of Cancer Immunotherapy.” Immunity 53, no. 4 (October 13, 2020): 824-839.e10. https://doi.org/10.1016/j.immuni.2020.09.006.
Samur, Mehmet Kemal, Anil Aktas Samur, Mariateresa Fulciniti, Raphael Szalat, Tessa Han, Masood Shammas, Paul Richardson, et al. “Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 38, no. 27 (September 20, 2020): 3107–18. https://doi.org/10.1200/JCO.20.00461.
Zajec, Marina, Kristine A. Frerichs, Martijn M. van Duijn, Inger S. Nijhof, Claudia A. M. Stege, Hervé Avet-Loiseau, Theo M. Luider, Yolanda B. de Rijke, Joannes F. M. Jacobs, and Niels W. C. J. van de Donk. “Cerebrospinal Fluid Penetrance of Daratumumab in Leptomeningeal Multiple Myeloma.” HemaSphere 4, no. 4 (August 2020): e413. https://doi.org/10.1097/HS9.0000000000000413.
Nakamura, Kyohei, Mark J. Smyth, and Ludovic Martinet. “Cancer Immunoediting and Immune Dysregulation in Multiple Myeloma.” Blood, July 9, 2020. https://doi.org/10.1182/blood.2020006540.
Di Bacco, Alessandra, Nizar J. Bahlis, Nikhil C. Munshi, Hervé Avet-Loiseau, Tamás Masszi, Luísa Viterbo, Ludek Pour, et al. “C-MYC Expression and Maturity Phenotypes Are Associated with Outcome Benefit from Addition of Ixazomib to Lenalidomide-Dexamethasone in Myeloma.” European Journal of Haematology 105, no. 1 (July 2020): 35–46. https://doi.org/10.1111/ejh.13405.
Mason, Mike J., Carolina Schinke, Christine L. P. Eng, Fadi Towfic, Fred Gruber, Andrew Dervan, Brian S. White, et al. “Multiple Myeloma DREAM Challenge Reveals Epigenetic Regulator PHF19 as Marker of Aggressive Disease.” Leukemia 34, no. 7 (July 2020): 1866–74. https://doi.org/10.1038/s41375-020-0742-z.
Corre, Jill, Lydia Montes, Elodie Martin, Aurore Perrot, Denis Caillot, Xavier Leleu, Karim Belhadj, et al. “Early Relapse after Autologous Transplant for Myeloma Is Associated with Poor Survival Regardless of Cytogenetic Risk.” Haematologica 105, no. 9 (June 5, 2020): e480-483. https://doi.org/10.3324/haematol.2019.236588.
Lemaitre, Léa, Laura Do Souto Ferreira, Marie-Véronique Joubert, Hervé Avet-Loiseau, Ludovic Martinet, Jill Corre, and Bettina Couderc. “Imprinting of Mesenchymal Stromal Cell Transcriptome Persists Even after Treatment in Patients with Multiple Myeloma.” International Journal of Molecular Sciences 21, no. 11 (May 28, 2020): 3854. https://doi.org/10.3390/ijms21113854.
Espagnolle, Nicolas, Benjamin Hebraud, Jean-Gérard Descamps, Mélanie Gadelorge, Marie-Véronique Joubert, Laura Do Souto Ferreira, Murielle Roussel, et al. “Functional Comparison between Healthy and Multiple Myeloma Adipose Stromal Cells.” Stem Cells International 2020 (March 5, 2020): 1–9. https://doi.org/10.1155/2020/4173578.
Avet-Loiseau, Herve, Heinz Ludwig, Ola Landgren, Bruno Paiva, Chris Morris, Hui Yang, Kefei Zhou, Sunhee Ro, and Maria-Victoria Mateos. “Minimal Residual Disease Status as a Surrogate Endpoint for Progression- Free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta- Analysis.” Clinical Lymphoma, Myeloma & Leukemia 20, no. 1 (January 2020): e30–37. https://doi.org/10.1016/j.clml.2019.09.622.
Rustad, Even H., Venkata Yellapantula, Daniel Leongamornlert, Niccolò Bolli, Guy Ledergor, Ferran Nadeu, Nicos Angelopoulos, et al. “Timing the Initiation of Multiple Myeloma.” Nature Communications 11, no. 1 (2020): 1917. https://doi.org/10.1038/s41467-020-15740-9.
Weisel, Katja, Andrew Spencer, Suzanne Lentzsch, Hervé Avet-Loiseau, Tomer M. Mark, Ivan Spicka, Tamas Masszi, et al. “Daratumumab, Bortezomib, and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis of CASTOR Based on Cytogenetic Risk.” Journal of Hematology & Oncology 13, no. 1 (2020): 115. https://doi.org/10.1186/s13045-020-00948-5.
Alberge, Jean-Baptiste, Florence Magrangeas, Mirko Wagner, Soline Denié, Catherine Guérin-Charbonnel, Loïc Campion, Michel Attal, et al. “DNA Hydroxymethylation Is Associated with Disease Severity and Persists at Enhancers of Oncogenic Regions in Multiple Myeloma.” Clinical Epigenetics 12, no. 1 (2020): 163. https://doi.org/10.1186/s13148-020-00953-y.
Soong, David, Jeran Stratford, Herve Avet-Loiseau, Nizar Bahlis, Faith Davies, Angela Dispenzieri, A. Kate Sasser, et al. “CNV Radar: An Improved Method for Somatic Copy Number Alteration Characterization in Oncology.” BMC Bioinformatics 21, no. 1 (2020): 98. https://doi.org/10.1186/s12859-020-3397-x.
Rustad, Even H., Venkata D. Yellapantula, Dominik Glodzik, Kylee H. Maclachlan, Benjamin Diamond, Eileen M. Boyle, Cody Ashby, et al. “Revealing the Impact of Structural Variants in Multiple Myeloma.” Blood Cancer Discovery 1, no. 3 (2020): 258–73. https://doi.org/10.1158/2643-3230.BCD-20-0132.
Braun, Matthias, Amelia Roman Aguilera, Ashmitha Sundarrajan, Dillon Corvino, Kimberley Stannard, Sophie Krumeich, Indrajit Das, et al. “CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells.” Immunity 53, no. 4 (2020): 805-823.e15. https://doi.org/10.1016/j.immuni.2020.09.010.
Terpos, Evangelos, Monika Engelhardt, Gordon Cook, Francesca Gay, Maria-Victoria Mateos, Ioannis Ntanasis-Stathopoulos, Niels W. C. J. van de Donk, et al. “Management of Patients with Multiple Myeloma in the Era of COVID-19 Pandemic: A Consensus Paper from the European Myeloma Network (EMN).” Leukemia 34, no. 8 (2020): 2000–2011. https://doi.org/10.1038/s41375-020-0876-z.
Adamia, Sophia, Ivane Abiatari, Samir B. Amin, Mariateresa Fulciniti, Stephane Minvielle, Cheng Li, Philippe Moreau, Herve Avet-Loiseau, Nikhil C. Munshi, and Kenneth C. Anderson. “The Effects of MicroRNA Deregulation on Pre-RNA Processing Network in Multiple Myeloma.” Leukemia 34, no. 1 (2020): 167–79. https://doi.org/10.1038/s41375-019-0498-5.
PUBLICATIONS 2019
Boyle, Eileen M., Xavier Leleu, Marie-Odile Petillon, Lionel Karlin, Chantal Doyen, Helene Demarquette, Bruno Royer, et al. “Daratumumab and Dexamethasone Is Safe and Effective for Triple Refractory Myeloma Patients: Final Results of the IFM 2014-04 (Etoile Du Nord) Trial.” British Journal of Haematology 187, no. 3 (November 2019): 319–27. https://doi.org/10.1111/bjh.16059.
Pertesi, Maroulio, Maxime Vallee, Xiaomu Wei, Maria V. Revuelta, Perrine Galia, Delphine Demangel, Javier Oliver, et al. “Exome Sequencing Identifies Germline Variants in DIS3 in Familial Multiple Myeloma.” Leukemia 33, no. 9 (September 2019): 2324–30. https://doi.org/10.1038/s41375-019-0452-6.
Henriot, Basile, Emmanuel Rouger, Chloe Rousseau, Martine Escoffre, Martine Sebillot, Claude Bendavid, Stephane Minvielle, Herve Avet-Loiseau, Olivier Decaux, and Caroline Moreau. “Prognostic Value of Involved/Uninvolved Free Light Chain Ratio Determined by Freelite and N Latex FLC Assays for Identification of High-Risk Smoldering Myeloma Patients.” Clinical Chemistry and Laboratory Medicine 57, no. 9 (August 27, 2019): 1397–1405. https://doi.org/10.1515/cclm-2018-1369.
Maura, Francesco, Niccolo Bolli, Nicos Angelopoulos, Kevin J. Dawson, Daniel Leongamornlert, Inigo Martincorena, Thomas J. Mitchell, et al. “Genomic Landscape and Chronological Reconstruction of Driver Events in Multiple Myeloma.” Nature Communications 10, no. 1 (August 23, 2019): 3835. https://doi.org/10.1038/s41467-019-11680-1.
Maura, Francesco, Andrea Degasperi, Ferran Nadeu, Daniel Leongamornlert, Helen Davies, Luiza Moore, Romina Royo, et al. “Author Correction: A Practical Guide for Mutational Signature Analysis in Hematological Malignancies.” Nature Communications 10, no. 1 (July 25, 2019): 3431. https://doi.org/10.1038/s41467-019-11468-3.
Munshi, Nikhil C., Sundar Jagannath, and Herve Avet-Loiseau. “Monoclonal Gammopathy May Be of Unpredictable Significance.” JAMA Oncology, July 18, 2019. https://doi.org/10.1001/jamaoncol.2019.1580.
Leleu, Xavier, Guillemette Fouquet, Valentine Richez, Stephanie Guidez, Alain Duhamel, Francois Machuron, Lionel Karlin, et al. “Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 25, no. 14 (July 15, 2019): 4224–30. https://doi.org/10.1158/1078-0432.CCR-18-3642.
Moreau, Philippe, Michel Attal, Cyrille Hulin, Bertrand Arnulf, Karim Belhadj, Lotfi Benboubker, Marie C. Bene, et al. “Bortezomib, Thalidomide, and Dexamethasone with or without Daratumumab before and after Autologous Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma (CASSIOPEIA): A Randomised, Open-Label, Phase 3 Study.” Lancet (London, England) 394, no. 10192 (July 6, 2019): 29–38. https://doi.org/10.1016/S0140-6736(19)31240-1.
Maura, Francesco, Andrea Degasperi, Ferran Nadeu, Daniel Leongamornlert, Helen Davies, Luiza Moore, Romina Royo, et al. “A Practical Guide for Mutational Signature Analysis in Hematological Malignancies.” Nature Communications 10, no. 1 (July 5, 2019): 2969. https://doi.org/10.1038/s41467-019-11037-8.
Perrot, Aurore, Valerie Lauwers-Cances, Elodie Tournay, Cyrille Hulin, Marie-Lorraine Chretien, Bruno Royer, Mamoun Dib, et al. “Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 37, no. 19 (July 1, 2019): 1657–65. https://doi.org/10.1200/JCO.18.00776.
Guillerey, Camille, Kyohei Nakamura, Andrea C. Pichler, Deborah Barkauskas, Sophie Krumeich, Kimberley Stannard, Kim Miles, et al. “Chemotherapy Followed by Anti-CD137 MAb Immunotherapy Improves Disease Control in a Mouse Myeloma Model.” JCI Insight 5 (June 13, 2019). https://doi.org/10.1172/jci.insight.125932.
Stannard, Kimberley A., Sébastien Lemoine, Nigel J. Waterhouse, Frank Vari, Lucienne Chatenoud, Maher K. Gandhi, Ludovic Martinet, Mark J. Smyth, and Camille Guillerey. “Human Peripheral Blood DNAM-1neg NK Cells Are a Terminally Differentiated Subset with Limited Effector Functions.” Blood Advances 3, no. 11 (June 11, 2019): 1681–94. https://doi.org/10.1182/bloodadvances.2018030676.
Neuzillet, Cindy, Annemilaï Tijeras-Raballand, Chanthirika Ragulan, Jérôme Cros, Yatish Patil, Matthieu Martinet, Mert Erkan, et al. “Inter- and Intra-Tumoural Heterogeneity in Cancer-Associated Fibroblasts of Human Pancreatic Ductal Adenocarcinoma.” The Journal of Pathology 248, no. 1 (May 2019): 51–65. https://doi.org/10.1002/path.5224.
Caillon, Helene, Herve Avet-Loiseau, Michel Attal, Philippe Moreau, Olivier Decaux, and Thomas Dejoie. “Comparison of Sebia Free Light Chain Assay With Freelite Assay for the Clinical Management of Diagnosis, Response, and Relapse Assessment in Multiple Myeloma.” Clinical Lymphoma, Myeloma & Leukemia 19, no. 5 (May 2019): e228–37. https://doi.org/10.1016/j.clml.2019.01.007.
Vergnolle, Ines, Jean-Baptiste Rieu, Herve Avet-Loiseau, Jill Corre, and Francois Vergez. “[Multiple myeloma immunophenotyping: method validation].” Annales de biologie clinique 77, no. 2 (April 1, 2019): 197–217. https://doi.org/10.1684/abc.2019.1426.
Aktas Samur, Anil, Stephane Minvielle, Masood Shammas, Mariateresa Fulciniti, Florence Magrangeas, Paul G. Richardson, Philippe Moreau, et al. “Deciphering the Chronology of Copy Number Alterations in Multiple Myeloma.” Blood Cancer Journal 9, no. 4 (March 26, 2019): 39. https://doi.org/10.1038/s41408-019-0199-3.
Thakurta, Anjan, Maria Ortiz, Pedro Blecua, Fadi Towfic, Jill Corre, Natalya V. Serbina, Erin Flynt, et al. “High Subclonal Fraction of 17p Deletion Is Associated with Poor Prognosis in Multiple Myeloma.” Blood 133, no. 11 (March 14, 2019): 1217–21. https://doi.org/10.1182/blood-2018-10-880831.
Avet-Loiseau, Herve. “Introduction to a Review Series on Advances in Multiple Myeloma.” Blood 133, no. 7 (February 14, 2019): 621. https://doi.org/10.1182/blood-2018-11-877795.
Corre, Jill, and Herve Avet-Loiseau. “Risk-Based Therapeutic Strategies.” Cancer Journal (Sudbury, Mass.) 25, no. 1 (February 2019): 54–58. https://doi.org/10.1097/PPO.0000000000000352.
Richez, Valentine, Cecile Gruchet, Stephanie Guidez, Guillemette Fouquet, Isabelle Azais, Geraldine Durand, Vincent Javaugue, et al. “Carfilzomib Weekly 20/56 Mg/m(2) , Lenalidomide and Dexamethasone for Early Relapsed Refractory Multiple Myeloma.” American Journal of Hematology 94, no. 1 (January 2019): E17–20. https://doi.org/10.1002/ajh.25327.
Walker, Brian A., Konstantinos Mavrommatis, Christopher P. Wardell, T. Cody Ashby, Michael Bauer, Faith Davies, Adam Rosenthal, et al. “A High-Risk, Double-Hit, Group of Newly Diagnosed Myeloma Identified by Genomic Analysis.” Leukemia 33, no. 1 (January 2019): 159–70. https://doi.org/10.1038/s41375-018-0196-8.

LES MEMBRES DE L’ÉQUIPE

Laure Buisson
Ingénieur ou technicien / Engineer and Technician
Corentin PIGNON
Ingénieur ou technicien / Engineer and Technician
Ludovic Martinet
Chercheur / Researcher
Eve Blanquart
Chercheur / Researcher
Liliana Lucca
Chercheur / Researcher
Marine Cuisinier
Ingénieur ou technicien / Engineer and Technician
Marie-Véronique Joubert
Ingénieur ou technicien / Engineer and Technician
Nadege Constantin Carrié
Ingénieur ou technicien / Engineer and Technician
Rüçhan Ekren
Etudiant ou stagiaire / PhD student and Trainee
Arthur Aubry
Chercheur / Researcher
Aurore Perrot
Enseignant-chercheur / Teacher-researcher

LES PARTENAIRES & FINANCIERS

Centre de Recherches en Cancérologie de Toulouse

Centre de Recherches en Cancérologie de Toulouse (Oncopole)

Toulouse - FR

Nous contacter

05 82 74 15 75

Envie de rejoindre
L’équipe du CRCT ?

Pin It on Pinterest